227 related articles for article (PubMed ID: 17210771)
1. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L
Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
3. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761
[TBL] [Abstract][Full Text] [Related]
5. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
Heinz WJ; Einsele H; Helle-Beyersdorf A; Zirkel J; Grau A; Schirmer D; Lenker U; Klinker H
Transpl Infect Dis; 2013 Oct; 15(5):449-56. PubMed ID: 23890126
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
Prattes J; Duettmann W; Hoenigl M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5595-9. PubMed ID: 27324763
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
[TBL] [Abstract][Full Text] [Related]
8. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.
Crombag MR; Huisman C; Kemper EM; Brüggemann RJ; Bijleveld YA
Ther Drug Monit; 2012 Jun; 34(3):320-5. PubMed ID: 22561586
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole.
Keating GM
Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
[TBL] [Abstract][Full Text] [Related]
12. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
Tragiannidis A; Herbrüggen H; Ahlmann M; Vasileiou E; Gastine S; Thorer H; Fröhlich B; Müller C; Groll AH
J Antimicrob Chemother; 2019 Dec; 74(12):3573-3578. PubMed ID: 31504563
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
Cornely OA; Helfgott D; Langston A; Heinz W; Vehreschild JJ; Vehreschild MJ; Krishna G; Ma L; Huyck S; McCarthy MC
Antimicrob Agents Chemother; 2012 May; 56(5):2652-8. PubMed ID: 22290953
[TBL] [Abstract][Full Text] [Related]
14. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jiménez JL; Candoni A; Raad I; Laverdiere M; Langston A; Kartsonis N; Van Iersel M; Connelly N; Waskin H
J Antimicrob Chemother; 2016 Mar; 71(3):718-26. PubMed ID: 26612870
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial.
Groll AH; Abdel-Azim H; Lehrnbecher T; Steinbach WJ; Paschke A; Mangin E; Winchell GA; Waskin H; Bruno CJ
Int J Antimicrob Agents; 2020 Sep; 56(3):106084. PubMed ID: 32682946
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area.
Vanstraelen K; Colita A; Bica AM; Mols R; Augustijns P; Peersman N; Vermeersch P; Annaert P; Spriet I
Pediatr Infect Dis J; 2016 Feb; 35(2):183-8. PubMed ID: 26544987
[TBL] [Abstract][Full Text] [Related]
18. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
[TBL] [Abstract][Full Text] [Related]
19. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
[TBL] [Abstract][Full Text] [Related]
20. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
